SCHEMBL4464412

SCHEMBL4464412

COc1cc2c(Oc3ccc(NC(=O)NCCC(C)(C)C)cc3)ccnc2cc1OCCN1CC(C)OC(C)C1

nearest known ligand 0.59

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PDGFRA P16234 13/20 0.59
KDR P35968 11/20 0.53
FGFR2 P21802 2/20 0.53
KIT P10721 2/20 0.51
MET P08581 5/20 0.51
HDAC1 Q13547 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13936829 0.96 PDGFRA (0.59) PDGFRAKDRFGFR2MET
SCHEMBL4465217 0.96 PDGFRA (0.59) PDGFRAKDRFGFR2MET
SCHEMBL4481067 0.92 PDGFRA (0.60) PDGFRAKDRFGFR2KITMET
SCHEMBL4488389 0.90 MET (0.57) PDGFRAKDRKITMET
SCHEMBL4477585 0.90 PDGFRA (0.49) PDGFRAKDRKITMET
SCHEMBL4484630 0.90 KDR (0.55) PDGFRAKDRFGFR2KITMET
SCHEMBL13936761 0.90 KDR (0.53) PDGFRAKDRFGFR2KITMET
SCHEMBL4466513 0.90 KDR (0.53) PDGFRAKDRFGFR2KITMET
SCHEMBL13936886 0.89 PDGFRA (0.57) PDGFRAKDRFGFR2KITMET
SCHEMBL4465851 0.89 PDGFRA (0.57) PDGFRAKDRFGFR2KITMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US claimed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2005-03-03 US disclosed
EP-1447405-A1 QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS KIRIN BEER KABUSHIKI KAISHA (JP) 2004-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors FGFR1, FGFR2, FGFR3 PDGFRA 372/4885KDR 211/4885FGFR2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.